MedTrace Logo

The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer

NCT03814447 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-08-10

No results posted yet for this study

Summary

The goal of this clinical trial is to study the safety and feasibility of anti- Mesothelin Chimeric Antigen Receptor T-Cell (MESO CAR-T cells) therapy for Refractory-Relapsed Ovarian Cancer

Conditions

Interventions

DRUG

anti- MESO CAR-T cells

Autologous genetically modified anti- MESO CAR transduced T cells

DRUG

Fludarabine

Dose: 30mg/m2/d

DRUG

Cyclophosphamide

Dose: 300mg/m2/d

Sponsors & Collaborators

  • Hrain Biotechnology Co., Ltd.

    collaborator INDUSTRY

  • Shanghai 6th People's Hospital

    lead OTHER

Principal Investigators

  • Hui Zhao, doctor · Shanghai 6th People's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-16
Primary Completion
2023-01-31
Completion
2023-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03814447 on ClinicalTrials.gov